ES2131073T3 - Metodo y composiciones para el tratamiento de la paralisis cerebral. - Google Patents

Metodo y composiciones para el tratamiento de la paralisis cerebral.

Info

Publication number
ES2131073T3
ES2131073T3 ES92919570T ES92919570T ES2131073T3 ES 2131073 T3 ES2131073 T3 ES 2131073T3 ES 92919570 T ES92919570 T ES 92919570T ES 92919570 T ES92919570 T ES 92919570T ES 2131073 T3 ES2131073 T3 ES 2131073T3
Authority
ES
Spain
Prior art keywords
compositions
treatment
brain paralysis
botulinum toxin
paralysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92919570T
Other languages
English (en)
Other versions
ES2131073T5 (es
Inventor
Herbert Kerr Graham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10701881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2131073(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2131073T3 publication Critical patent/ES2131073T3/es
Publication of ES2131073T5 publication Critical patent/ES2131073T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

El uso de una neurotoxina presináptica que es una toxina botulínica, para la fabricación de un medicamento para la promoción del crecimiento muscular normal en un paciente joven antes de que el paciente haya completado su periodo de crecimiento y haya habido contracturas fijas, que padece de contracturas dinámicas debido a la parálisis cerebral.
ES92919570T 1991-09-24 1992-09-16 Uso de una neurotoxina presinaptica para el tratamiento de la paralisis cerebral. Expired - Lifetime ES2131073T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919120306A GB9120306D0 (en) 1991-09-24 1991-09-24 Method and compositions for the treatment of cerebral palsy
GB9120306 1991-09-24

Publications (2)

Publication Number Publication Date
ES2131073T3 true ES2131073T3 (es) 1999-07-16
ES2131073T5 ES2131073T5 (es) 2007-06-16

Family

ID=10701881

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92919570T Expired - Lifetime ES2131073T5 (es) 1991-09-24 1992-09-16 Uso de una neurotoxina presinaptica para el tratamiento de la paralisis cerebral.

Country Status (13)

Country Link
US (7) US6395277B1 (es)
EP (1) EP0605501B2 (es)
JP (2) JP3535872B2 (es)
AT (1) ATE178799T1 (es)
AU (1) AU666334B2 (es)
CA (1) CA2119562C (es)
DE (1) DE69228938T3 (es)
DK (1) DK0605501T5 (es)
ES (1) ES2131073T5 (es)
GB (1) GB9120306D0 (es)
GR (1) GR3030418T3 (es)
NO (2) NO312747B1 (es)
WO (1) WO1993005800A1 (es)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US7384918B2 (en) * 1991-09-24 2008-06-10 Allergan, Inc. Botulinum toxin for treating muscle contracture
US6939852B2 (en) * 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
CA2138020C (en) * 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
AU683275B2 (en) * 1993-06-10 1997-11-06 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
EP1374886B1 (en) * 1993-06-10 2009-09-02 Allergan, Inc. Treatment of neuromuscular disorders and conditions with different botulinum serotype
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
ES2339865T3 (es) * 1993-12-28 2010-05-26 Allergan, Inc. Uso del componente neurotoxico de toxinas botulinicas para el tratamiento de musculos espasticos.
US8557256B2 (en) * 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US8187612B2 (en) * 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
AU2007202480B2 (en) * 1993-12-28 2009-01-29 Allergan, Inc. Method for treating pain associated with a muscle disorder
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
DK1086702T3 (da) * 1994-05-09 2005-05-23 William J Binder Præsynaptiske neurotoksiner til behandling af migrænehovedpine
CN1176658A (zh) * 1994-10-24 1998-03-18 蛇药制品有限公司 治疗和预防艰难梭菌疾病的疫苗和抗毒素
EP1053014A4 (en) 1998-01-26 2004-11-10 Univ Massachusetts BIOLOGICALLY ACTIVE HEMAGGLUTININE TYPE A i (STRIDIUM BOTULINUM) AND METHOD FOR ITS USE
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6337075B1 (en) * 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US7494661B2 (en) * 2000-06-28 2009-02-24 Ira Sanders Methods for using tetanus toxin for beneficial purposes in animals (mammals)
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US7691983B2 (en) 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
IL154044A0 (en) * 2000-07-21 2003-07-31 Essentia Biosystems Inc Multi-component pharmaceutical compositions containing a complex of a positively charged backbone and a negatively charged backbone and methods for the preparation thereof
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
ITUD20010002A1 (it) 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
ES2401570T3 (es) * 2001-11-15 2013-04-22 Phytotox Limited Composiciones farmacéuticas que contienen 3,4-propinoperhidropurinas y usos de las mismas para bloquear la transmisión neuronal
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
AU2003221050A1 (en) * 2002-03-29 2003-10-13 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Remedy for hypermyotonia
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US6776991B2 (en) 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
BR0316871A (pt) * 2002-12-20 2005-10-18 Botulinum Toxin Res Ass Inc Composições farmacêuticas aperfeiçoadas de toxina botulìnica
BRPI0408131A (pt) * 2003-03-06 2006-03-01 Botulinum Toxin Res Ass Inc tratamento com toxina botulina de dor facial e cefaléia crÈnicas relacionadas com sinusite
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US7393538B2 (en) * 2003-04-25 2008-07-01 Ackerman Alan H Clostridial toxin treatment for dermatillomania
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7220422B2 (en) 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US20050013850A1 (en) * 2003-07-15 2005-01-20 Caers Jan K. Device to assist hyperhydrosis therapy
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20050148935A1 (en) * 2003-12-29 2005-07-07 Rozalina Dimitrova Botulinum toxin injection guide
MXPA06009897A (es) 2004-03-03 2008-02-07 Revance Therapeutics Inc Composiciones y metodos para el diagnostico topico y el transporte terapeutico.
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
TR201815364T4 (tr) 2004-03-03 2018-11-21 Revance Therapeutics Inc Botulinum toksinlerinin topikal uygulaması ve transdermal dağıtımı.
US20050206225A1 (en) * 2004-03-18 2005-09-22 Ford Global Technologies, Llc Method and apparatus for predicting the position of a trailer relative to a vehicle
CN101123967A (zh) * 2004-05-07 2008-02-13 菲特托克斯有限公司 藻毒素的经皮给药
JP5047782B2 (ja) * 2004-05-07 2012-10-10 ファイトトックス リミテッド フィコトキシン及びその使用
US20080045889A1 (en) * 2004-07-21 2008-02-21 Gerondale Scott J Botoxo Needle Injector
US20060024794A1 (en) * 2004-07-30 2006-02-02 Shengwen Li Novel methods for production of di-chain botulinum toxin
ZA200707351B (en) * 2005-03-03 2010-02-24 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of an oligopeptide
KR101453963B1 (ko) 2005-03-03 2014-10-22 레반스 테라퓨틱스, 아이엔씨. 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및 방법
CN103315954A (zh) * 2005-07-18 2013-09-25 麻萨诸塞州洛厄尔大学 制备与使用纳米乳剂的组合物和方法
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
EP1906923B1 (en) 2005-07-22 2018-01-24 The Foundry, LLC Systems and methods for delivery of a therapeutic agent
US9511210B2 (en) * 2006-05-19 2016-12-06 The Foundry, Llc Apparatus for toxin delivery to the nasal cavity
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US7910116B2 (en) * 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
BRPI0618753A2 (pt) * 2005-11-17 2011-09-13 Revance Therapeutics Inc composição para liberação transdérmica de toxina botulìnica e método de administração
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
EP1959994B1 (en) 2005-12-01 2017-08-30 University Of Massachusetts Lowell Botulinum nanoemulsions
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US7811586B2 (en) 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
SG179457A1 (en) 2006-12-01 2012-04-27 Anterios Inc Peptide nanoparticles and uses therefor
CA2671447A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
US20080233152A1 (en) * 2006-12-29 2008-09-25 Revance Therapeutics, Inc. Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabilized with Polypeptide Fragments Derived from HIV-TAT
KR20090102833A (ko) * 2006-12-29 2009-09-30 레반스 테라퓨틱스, 아이엔씨. 역서열 ｈｉｖ-ｔａｔ 폴리펩티드를 이용한 수송 분자
KR20100050443A (ko) 2007-05-31 2010-05-13 안테리오스, 인코퍼레이티드 핵산 나노입자 및 이의 용도
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
EP2320821B2 (en) 2008-05-09 2020-12-30 Nuvaira, Inc. Systems for treating a bronchial tree
SG10201608732VA (en) * 2008-06-26 2016-12-29 Anterios Inc Dermal delivery
JP5752598B2 (ja) 2008-09-11 2015-07-22 アイ．ビー．アール． イスラエリ バイオテクノロジー リサーチ リミテッド レウコユム球根の抽出物及びその利用
US8506970B2 (en) * 2008-10-14 2013-08-13 Dt Scimed, Llc Dose and localization of botulinum toxins in skin and muscle
JP4697289B2 (ja) 2008-11-05 2011-06-08 ソニー株式会社 撮像装置、撮像装置の表示制御方法
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
CA2745657C (en) 2008-12-04 2022-06-21 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
JP5843777B2 (ja) 2009-10-27 2016-01-13 ホライラ， インコーポレイテッド 冷却可能なエネルギー放出アセンブリを有する送達デバイス
EP2498705B1 (en) 2009-11-11 2014-10-15 Holaira, Inc. Device for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US8992941B2 (en) 2011-07-08 2015-03-31 Allergan, Inc. Method for treatment of esophageal spasm
AU2012282873B2 (en) 2011-07-08 2016-03-31 Allergan, Inc. Method for treatment of autonomic nervous system disorders
AU2012280947B2 (en) 2011-07-14 2016-04-07 Allergan, Inc. Methods for treatment of incontinence associated with sexual activity
MX2014000612A (es) 2011-07-20 2014-02-27 Allergan Inc Toxinas botulinicas para usar en un metodo para el tratamiento de depositos adiposos.
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
WO2014048740A1 (en) 2012-09-25 2014-04-03 Haldor Topsøe A/S Steam reforming catalyst and method of making thereof
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
CA2991529C (en) 2015-07-08 2021-01-05 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder, gait and limb impairment treatment
BR112019010131A2 (pt) 2016-11-21 2019-10-08 Eirion Therapeutics Inc entrega transdérmica de agentes grandes
WO2019226858A1 (en) * 2018-05-24 2019-11-28 Children's Hospital Medical Center Compositions and methods for the treatment of muscle contractures
CN116348480A (zh) * 2020-10-07 2023-06-27 普罗塔克斯公司 肉毒杆菌毒素的真空干燥方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2373454A (en) * 1943-07-09 1945-04-10 Squibb & Sons Inc Method of preparing tetanus toxin
US2719102A (en) * 1949-10-28 1955-09-27 Corn States Serum Company Clostridium perfringens toxoid and process of making the same
US3132995A (en) * 1961-10-20 1964-05-12 Carter Prod Inc Endotoxin fractions and method for producing same
US4234566A (en) * 1979-06-29 1980-11-18 Packman Elias W Antihistamine and methods for use thereof
US4720494A (en) * 1984-11-05 1988-01-19 The Gillette Company Anticholinergic eucatropine esters and antiperspirant use thereof
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
EP0262396A3 (de) 1986-09-20 1989-08-23 Heinz Dipl.-Ing. Hölter Verfahren zum Herstellen von Calciumsulfatdihydrat bei der Rauchgasentschwefelung
US5055291A (en) * 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4935969A (en) * 1987-12-02 1990-06-26 Farnsworth Orin J Method and device for the controlled disposal of human waste
US4932936A (en) * 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
US5053005A (en) * 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5056291A (en) * 1989-10-19 1991-10-15 Skilland Engineering, Ltd. Modular system for space frame structures
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US7384918B2 (en) * 1991-09-24 2008-06-10 Allergan, Inc. Botulinum toxin for treating muscle contracture
US6939852B2 (en) * 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
FR2692475B1 (fr) 1992-06-19 2000-04-21 Montpellier Chirurgie Prothese totale du genou.
CA2138020C (en) 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
JPH06192296A (ja) 1992-10-28 1994-07-12 Chiba Pref Gov 治療用医薬品としての結晶ａ型ボツリヌス毒素の製造法。
AU6030494A (en) 1993-01-15 1994-08-15 Associated Synapse Biologics Method for treating myofascial pain syndrome
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
EP1374886B1 (en) 1993-06-10 2009-09-02 Allergan, Inc. Treatment of neuromuscular disorders and conditions with different botulinum serotype
AU683275B2 (en) 1993-06-10 1997-11-06 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US8187612B2 (en) * 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US8557256B2 (en) * 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US6986893B2 (en) * 1993-12-28 2006-01-17 Allergan, Inc. Method for treating a mucus secretion
ES2339865T3 (es) 1993-12-28 2010-05-26 Allergan, Inc. Uso del componente neurotoxico de toxinas botulinicas para el tratamiento de musculos espasticos.
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
DK1086702T3 (da) 1994-05-09 2005-05-23 William J Binder Præsynaptiske neurotoksiner til behandling af migrænehovedpine
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6500436B2 (en) * 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
TWI243265B (en) 2002-02-27 2005-11-11 Chi Mei Optoelectronics Corp Method for forming a reflection-type light diffuser

Also Published As

Publication number Publication date
DE69228938T2 (de) 1999-09-23
NO312747B1 (no) 2002-07-01
US20050112146A1 (en) 2005-05-26
EP0605501A1 (en) 1994-07-13
US20010046962A1 (en) 2001-11-29
NO20013727D0 (no) 2001-07-30
ES2131073T5 (es) 2007-06-16
AU666334B2 (en) 1996-02-08
ATE178799T1 (de) 1999-04-15
US6448231B2 (en) 2002-09-10
JPH06510779A (ja) 1994-12-01
GR3030418T3 (en) 1999-09-30
JP3535872B2 (ja) 2004-06-07
JP2002097154A (ja) 2002-04-02
GB9120306D0 (en) 1991-11-06
AU2566492A (en) 1993-04-27
DE69228938D1 (de) 1999-05-20
DK0605501T3 (da) 1999-10-25
CA2119562A1 (en) 1993-04-01
US20050142150A1 (en) 2005-06-30
EP0605501B2 (en) 2006-11-29
NO324159B1 (no) 2007-09-03
EP0605501B1 (en) 1999-04-14
US20080206224A1 (en) 2008-08-28
US6395277B1 (en) 2002-05-28
NO941065L (no) 1994-03-23
NO941065D0 (no) 1994-03-23
US20070224221A1 (en) 2007-09-27
DE69228938T3 (de) 2008-01-03
NO20013727L (no) 1994-03-23
CA2119562C (en) 2005-02-15
US7378389B2 (en) 2008-05-27
US20020142010A1 (en) 2002-10-03
DK0605501T5 (da) 2007-02-26
WO1993005800A1 (en) 1993-04-01

Similar Documents

Publication Publication Date Title
ES2131073T3 (es) Metodo y composiciones para el tratamiento de la paralisis cerebral.
MXPA03002576A (es) Metodos para tratar lesiones musculares.
HUT59313A (en) Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions
DE69109376T2 (de) Hemmung von Muskelschwund und Proteinabbau von Muskeln bei Säugetieren durch Tetrazyklines.
DE69428523T2 (de) Verfahren zur behandlung von gemüts- oder geisteskrankheiten und von gemüts- oder geisteskrankheiten, die von anfällen begleitet sind
FI943805A0 (fi) Substituoituja adeniinijohdannaisten käyttö multippeliskleroosin hoitoon
ES2194025T3 (es) Toxinas botulinicas multiples para tratar trastornos y enfermedades neuromusculares.
PT95117A (pt) Metodo para o tratamento da ejaculacao precoce utilizando sertralina
ATE190840T1 (de) Zusammensetzung zur behandlung der parkinson- krankheit
ZA896558B (en) Method of treating skin injuries using thromboxane a2 receptor antagonists
DK71387A (da) Terapeutisk middel til behandling af psoriasis
BR9500436A (pt) Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico
DE68919673D1 (de) Verfahren zur behandlung und vorbeugung des verlustes von knochenmasse.
DE69424679D1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
ZA837972B (en) Method of analgesic treatment and pharmaceutical compositions
PT1007085E (pt) Utilizacao da hormona de crescimento em composicoes para o tratamento da resistencia a insulina no coracao
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
DK0659079T3 (da) Transdermalt terapeutisk system med pentylentetrazol som aktivt stof.
BRPI0519459A2 (pt) uso de certos compostos de bifenila para proteÇço dos neurânios e oligodendràcitos no tratamento da esclerose méltipla (em)
UA41153A (uk) Спосіб немедикаментозного лікування симпато-адреналових пароксизмів
YU104192A (sh) 2-(4-hidroksipiperiodino)-1-alkanol derivati

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 605501

Country of ref document: ES